BOLD
Boundless Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.87
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 901.0K | 1.3M | 1.1M | — | — |
| Gross Profit | (901.0K) | (1.3M) | (1.1M) | — | — |
| Operating Expenses | |||||
| R&D Expense | 44.5M | 44.8M | 55.3M | 42.6M | 37.2M |
| SG&A Expense | 23.8M | 18.7M | 18.0M | 12.2M | 9.3M |
| General & Admin Expense | 23.8M | 18.7M | 18.0M | 12.2M | 9.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.2M) | (1.3M) | (1.1M) | — | — |
| Total Operating Expenses | 67.1M | 62.3M | 72.2M | 54.8M | 46.5M |
| Cost and Expenses | 68.0M | 63.6M | 73.3M | 54.8M | 46.5M |
| Operating Income (EBIT) | (68.0M) | (63.6M) | (73.3M) | (54.8M) | (46.5M) |
| Non-Operating | |||||
| Interest Income | 4.0M | 5.4M | 7.9M | 5.3M | 668.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 4.0M | 5.4M | 7.9M | 5.3M | 668.0K |
| Other Non-Op Income/Expense | 4.0M | 5.4M | 7.9M | 5.4M | 568.0K |
| Non-Operating Income (excl Interest) | (4.0M) | (5.4M) | (7.9M) | (5.4M) | (568.0K) |
| EBT (Pre-Tax Income) | (64.0M) | (58.2M) | (65.4M) | (49.4M) | (45.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (64.0M) | (58.2M) | (65.4M) | (49.4M) | (45.9M) |
| Earnings from Cont. Ops | (64.0M) | (58.2M) | (65.4M) | (49.4M) | (45.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (64.0M) | (58.2M) | (65.4M) | (49.4M) | (45.9M) |
| Per Share | |||||
| Basic EPS | ($2.86) | ($2.60) | ($3.85) | ($2.22) | ($2.06) |
| Diluted EPS | ($2.86) | ($2.60) | ($3.85) | ($2.22) | ($2.06) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 22.4M | 22.4M | 17.0M | 22.2M | 22.2M |
| Diluted Shares Outstanding | 22.4M | 22.4M | 17.0M | 22.2M | 22.2M |
| Profitability Metrics | |||||
| EBITDA | (58.6M) | (56.9M) | (64.3M) | (48.5M) | (45.0M) |
| D&A | 5.4M | 1.3M | 1.1M | 957.0K | 942.0K |
| EBIT | (64.0M) | (58.2M) | (65.4M) | (49.4M) | (45.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026